Aspyrian Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aspyrian Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013162
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a biotechnology company which develops precision targeted medicines to handle both the primary tumor and systemic disease. Its lead pipeline product, RM-1929, is under development for the treatment of different cancer types, including cancers of the head and neck, colon, esophagus, lung and pancreas. The company develops oncology targeted approaches based on its photoimmunotherapy platform. Aspyrian Therapeutics’ photoimmunotherapy technology comprises laser activated monoclonal antibody conjugates. The antibody conjugates utilizes a photoactivatable molecule and acquires anticancer activity to target a broad range of cancer antigens and tumor types. Aspyrian Therapeutics is headquartered in San Diego, California, the US.

Aspyrian Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Aspyrian Therapeutics Raises USD15 Million in Series B-1 Financing 10
Aspyrian Therapeutics Raises Additional USD15.2 Million in Series B Venture Financing 11
Aspyrian Therapeutics Raises USD40 Million in Series B Financing Round 12
Aspyrian Therapeutics Raises USD4.25 Million in Extended Series A Financing 13
Aspyrian Therapeutics Raises USD2 Million in Venture Financing 14
Licensing Agreements 15
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 15
Aspyrian Therapeutics Inc – Key Competitors 16
Aspyrian Therapeutics Inc – Key Employees 17
Aspyrian Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aspyrian Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aspyrian Therapeutics Raises USD15 Million in Series B-1 Financing 10
Aspyrian Therapeutics Raises Additional USD15.2 Million in Series B Venture Financing 11
Aspyrian Therapeutics Raises USD40 Million in Series B Financing Round 12
Aspyrian Therapeutics Raises USD4.25 Million in Extended Series A Financing 13
Aspyrian Therapeutics Raises USD2 Million in Venture Financing 14
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 15
Aspyrian Therapeutics Inc, Key Competitors 16
Aspyrian Therapeutics Inc, Key Employees 17

★海外企業調査レポート[Aspyrian Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TELUS Corporation:企業の戦略・SWOT・財務情報
    TELUS Corporation - Strategy, SWOT and Corporate Finance Report Summary TELUS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • SPX Flow Inc (FLOW):企業の財務・戦略的SWOT分析
    SPX Flow Inc (FLOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Foley Family Wines Limited:企業の戦略・SWOT・財務分析
    Foley Family Wines Limited - Strategy, SWOT and Corporate Finance Report Summary Foley Family Wines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • S-Oil Corporation Inc (010950):企業の財務・戦略的SWOT分析
    S-Oil Corporation Inc (010950) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ezz Steel Company SAE:企業の戦略・SWOT・財務情報
    Ezz Steel Company SAE - Strategy, SWOT and Corporate Finance Report Summary Ezz Steel Company SAE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • InCarda Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary InCarda Therapeutics Inc (InCarda) is a biopharmaceutical company that concentrates on the development of transformative therapies for cardiovascular conditions through the inhalation route. The company’s lead product candidate includes InRhythm, an inhaled antiarrhythmic for acute treatment …
  • Toyobo Co Ltd (3101):企業の財務・戦略的SWOT分析
    Toyobo Co Ltd (3101) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • BFS Group Limited:企業の戦略・SWOT・財務情報
    BFS Group Limited - Strategy, SWOT and Corporate Finance Report Summary BFS Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Corporate Office Properties Trust:企業の戦略・SWOT・財務情報
    Corporate Office Properties Trust - Strategy, SWOT and Corporate Finance Report Summary Corporate Office Properties Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • General Dynamics Land Systems Inc:企業の戦略・SWOT・財務情報
    General Dynamics Land Systems Inc - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Land Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • easyJet Plc:企業の戦略・SWOT・財務情報
    easyJet Plc - Strategy, SWOT and Corporate Finance Report Summary easyJet Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • T7 Global Berhad (T7GLOBAL):石油・ガス:M&Aディール及び事業提携情報
    Summary T7 Global Berhad (T7 Global), formerly Tanjung Offshore Berhad, is an oil and gas company that offers gas generators and integrated services. The company's services include topside maintenance, engineering and procurement, installation and commissioning, initial engineering design layout, pr …
  • Kaiser Foundation Health Plan of Washington:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Carondelet Health Network-製薬・医療分野:企業M&A・提携分析
    Summary Carondelet Health Network (Carondelet) is a healthcare service organization that serves through its network of hospitals including St. Mary’s Hospital, St. Joseph’s Hospital and Holy Cross Hospital. The organization provides a wide range of medical and treatment services such as neurology or …
  • Lukoil Oil Co (LKOH):企業の財務・戦略的SWOT分析
    Lukoil Oil Co (LKOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cooper Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Cooper Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Cooper Energy Limited (CEL) is an exploration and production company that offers oil production programs. The company explores, produces, and commercializes crude oil and natural gas products. It condu …
  • Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Bial - Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants …
  • China Daye Non-Ferrous Metals Mining Limited:企業の戦略・SWOT・財務情報
    China Daye Non-Ferrous Metals Mining Limited - Strategy, SWOT and Corporate Finance Report Summary China Daye Non-Ferrous Metals Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • PharmaCyte Biotech Inc (PMCB)-医療機器分野:企業M&A・提携分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company’s technology is used for the treatment of advanced and inoperable pancreatic cancer, and diabetes. It develops …
  • Genera Biosystems Ltd (GBI):製薬・医療:M&Aディール及び事業提携情報
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆